Mixed connective tissue disease medical therapy
|
Mixed connective tissue disease Microchapters |
|
Differentiating Mixed connective tissue disease from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Mixed connective tissue disease medical therapy On the Web |
|
American Roentgen Ray Society Images of Mixed connective tissue disease medical therapy |
|
Directions to Hospitals Treating Mixed connective tissue disease |
|
Risk calculators and risk factors for Mixed connective tissue disease medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Shaghayegh Habibi, M.D.[2]
Overview
The treatment of patients with MCTD is organ specific and depends on kind of internal organ involvement, phase of the disease, and rate of progression. Treatment strategies must follow conventional therapies that are used for similar problems in other rheumatic diseases (systemic lupus erythematosus, scleroderma, polymyositis). Patients usually react to low doses of steroids and non-steroidal anti-inflammatory drugs, in combination with immunosuppressive drugs or biologic agents. In refractory cases or in severe clinical conditions, immunoglobulins, cytotoxic agents or biologic drugs can be administered.
Medical Therapy
- The treatment of patients with MCTD depends on:[1]
- Type of Internal organ involvement
- Phase of the disease
- Rate of disease progression
- Treatment strategies must follow conventional treatments that are used for similar problems in other rheumatic diseases (SLE, scleroderma, polymyositis).[2]
- For more information about treatment of systemic lupus erythematosus click here.
- For more information about treatment of scleroderma click here.
- For more information about treatment of polymyositis click here.
- Usually the treatment of patients with MCTD include:[1]
- Low doses of steroids
- Non-steroidal anti-inflammatory drugs
- Immunosuppressive drugs
- Biologic agents (monoclonal antibodies)
- The treatment options in refractory cases or in severe clinical conditions include:[3]
- Immunoglobulins
- Cytotoxic agents (such as cyclophosphamide)
- Biologic drugs
- Plasmapheresis may be a therapeutic option, especially when it is combined with agents that can block production of pathogenic autoantibodies, such as rituximab (a monoclonal antibody anti-CD20 which can modulate the disease activity).
References
- ↑ 1.0 1.1 Latuśkiewicz-Potemska J, Zygmunt A, Biernacka-Zielińska M, Stańczyk J, Smolewska E (October 2013). "Mixed connective tissue disease presenting with progressive scleroderma symptoms in a 10-year-old girl". Postepy Dermatol Alergol. 30 (5): 329–36. doi:10.5114/pdia.2013.38365. PMC 3858664. PMID 24353496.
- ↑ Kim P, Grossman JM (August 2005). "Treatment of mixed connective tissue disease". Rheum. Dis. Clin. North Am. 31 (3): 549–65, viii. doi:10.1016/j.rdc.2005.04.008. PMID 16084325.
- ↑ Latuśkiewicz-Potemska J, Zygmunt A, Biernacka-Zielińska M, Stańczyk J, Smolewska E (October 2013). "Mixed connective tissue disease presenting with progressive scleroderma symptoms in a 10-year-old girl". Postepy Dermatol Alergol. 30 (5): 329–36. doi:10.5114/pdia.2013.38365. PMC 3858664. PMID 24353496.